Simple tests can identify blood clots related to COVID-19: Examination | Health

Researchers have used a minimally invasive test to identify blood clots in small blood vessels in the skin of patients with severe COVID-19 who appeared to be normal, according to a study. These blood clots were not seen in the skin of patents with other types of severe infectious lung disease or in people with only mild or moderate COVID-19, the researchers said. (Also read: Covid increases the risk of blood clots for up to six months: study)

A skin biopsy is a procedure to remove cells or skin samples from for laboratory examination.

The researchers said that a skin biopsy can help assess tissue damage related to COVID-19 as well as help distinguish this blood pathology from other forms of serious respiratory disease.

Prior to this study, recently published in The American Journal of Pathology, invasive procedures such as nerve, kidney or lung biopsy would have been required.

“We were the first group to recognize that lung disease in acute COVID-19 was different from other serious critical respiratory infections and that the unusual pathology was systemic,” said study leader Jeffrey Laurence, of the Weill Cornell Medicine Institute in the United States. .

The researchers collected 4 millimeter (mm) biopsy samples of normal-looking skin from 15 patients on intensive care with COVID-19 and six patients with mild to moderate disease symptoms, such as fever, chills, cough or shortness of breath.

Biopsy samples from nine inpatients with severe or critical respiratory or kidney disease who died before the COVID-19 era were also included in the study.

The researchers found that microthrombi or small blood clots were detected in 13 of the 15 patients with severe or critical COVID-19.

No microthrombi was detected in biopsies of patients who had mild to moderate COVID-19 or patients from the pre-COVID-19 era with severe respiratory disease or kidney disease, the researchers said.

It is likely that these microvascular changes may be a unique feature of COVID-19 respiratory disorder compared to other acute respiratory diseases, they said.

An antiviral protein capable of blocking SARS-CoV-2 growth, MxA, was found in all six mild to moderate COVID-19 patients, indicating that their immune system was actively fighting the virus, against only two patients with serious to critical illness, according to the researchers.

An interferon-induced inflammatory protein, SIN3A, was prominent in the microvascular skin with normal appearance from patients with severe or critical COVID-19, but not in similar samples from normal controls, they said.

Interferons and cytokines are molecules that are essential for the appropriate response to pathogens, damaged cells, or irritants in inflammatory responses.

Increased plasma SN3A levels and expression in the small skin vessels were associated with the severity of the patient’s disease and could contribute to the cytokine storm characteristic of such patients.

A cytokine storm is a severe immune reaction in which the body releases too many cytokines into the bloodstream too quickly.

Laurence notes that these results have clinical implications.

“Although anticoagulants were used in the pre-COVID-19 era in sepsis-associated pneumonia to reduce macrophage thromboembolism, most randomized trials to date have not found that this treatment benefits inpatients who are critically ill with COVID-19. acute respiratory distress syndrome.

“These drugs may not be able to reduce microvascular thrombosis found with SARS-CoV-2 infection,” he added.

This story has been published from a wire agency feed with no changes to the text. Only the heading has been changed.

Leave a Comment